These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23799525)

  • 1. Idiopathic myelofibrosis in children: primary myelofibrosis, essential thrombocythemia, or transient process?
    Slone JS; Smith MC; Seegmiller AC; Sidonio RF; Yang E
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):559-65. PubMed ID: 23799525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Myeloproliferative disorders].
    Binder D; Fehr J
    Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
    J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
    Muth M; Engelhardt BM; Kröger N; Hussein K; Schlué J; Büsche G; Kreipe HH; Bock O
    Ann Hematol; 2011 Jan; 90(1):33-40. PubMed ID: 20625903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Leukemia; 2013 Oct; 27(10):1953-8. PubMed ID: 23467025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The myeloproliferative disorders.
    Gilbert HS; Dameshek W
    Dis Mon; 1970 Oct; ():1-52. PubMed ID: 4921953
    [No Abstract]   [Full Text] [Related]  

  • 14. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retrospective analysis of the clinical course of 12 children given the diagnosis essential thrombocythemia].
    Kratz CP; Abd El-Monheim A; Manke EM; Rister M; Rogge T; Niemeyer CM
    Klin Padiatr; 2004; 216(6):349-55. PubMed ID: 15565550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
    Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
    Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
    Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.
    Plo I; Vainchenker W
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S329-39. PubMed ID: 19778861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prefibrotic myelofibrosis: treatment algorithm 2018.
    Finazzi G; Vannucchi AM; Barbui T
    Blood Cancer J; 2018 Nov; 8(11):104. PubMed ID: 30405096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.